![]() |
|
|
Vol. 29, Issue 4, 415-421, April 2001
Drug Metabolism and Pharmacokinetics, Preclinical Safety
(M.L.W., B.A.O., L.C.R., E.D.G., J.B.M.), Clinical Pharmacology, and
Clinical Research (J.F.M.), Novartis Institute for Biomedical Research,
East Hanover, New Jersey; and Core Technologies (J.A.C.,
M.J.S.), Novartis Institute for Biomedical Research, Summit, New
Jersey
The pharmacokinetics and metabolism of nateglinide were studied in
six healthy male subjects receiving a single oral (120 mg) and
intravenous (60 mg) dose of [14C]nateglinide in
randomized order. Serial blood and complete urine and feces were
collected for 120 h post dose. Nateglinide was rapidly (~90%)
absorbed, with peak blood and plasma concentrations at ~1 h post
dose. The maximal plasma concentrations of radioactivity (6360 ngEq/ml)
and nateglinide (5690 ng/ml) were comparable, and plasma radioactivity
concentrations were about twice those of blood at all times. Oral
bioavailability was 72%, indicating only a modest first-pass effect.
After either dose, plasma nateglinide concentrations declined rapidly
with elimination half-lives of 1.5 to 1.7 h and plasma clearance
of 7.4 l/h. Plasma radioactivity was eliminated more slowly with
half-lives of 52 and 35 h in plasma and blood, respectively, after
the oral dose. The contribution of this more slowly eliminated
component to the AUC0-
was minor. Nateglinide was
extensively metabolized, with excretion predominantly (84-87%) in
urine. Only ~16% of the dose was excreted unchanged in urine after
either dosing route. The major metabolites were the result of oxidative
modifications of the isopropyl group. Three of these were
monohydroxylated, two of which appeared to be diastereoisomers.
Additionally, one metabolite with an unsaturation in the isopropyl
group and two diol-containing isomers were identified. Glucuronic acid
conjugates resulting from direct glucuronidation of the carboxylic acid
were also present. The major metabolite in plasma and urine was the
result of hydroxylation of the methine carbon of the isopropyl group.
This article has been cited by other articles:
![]() |
M. Scarsi, M. Podvinec, A. Roth, H. Hug, S. Kersten, H. Albrecht, T. Schwede, U. A. Meyer, and C. Rucker Sulfonylureas and Glinides Exhibit Peroxisome Proliferator-Activated Receptor {gamma} Activity: A Combined Virtual Screening and Biological Assay Approach Mol. Pharmacol., February 1, 2007; 71(2): 398 - 406. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Devineni, Y. H. Walter, H. T. Smith, J. S. Lee, P. Prasad, and J. F. McLeod Pharmacokinetics of Nateglinide in Renally Impaired Diabetic Patients J. Clin. Pharmacol., February 1, 2003; 43(2): 163 - 170. [Abstract] [Full Text] |
||||